2 results match your criteria: "Universitaire Paris 6[Affiliation]"
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia.
Clin Cancer Res
November 2005
Laboratoire Institut National de la Sante et de la Recherche Medicale (INSERM U736), Universitaire Paris 6 (UMR 736), France.
Purpose: P-Glycoprotein (Pgp) is associated with poor outcome in acute myeloid leukemia (AML). We have investigated other ATP-binding cassette proteins such as BCRP, MRP1, MRP2, MRP3, and MRP5 for their potential implication in chemoresistance.
Experimental Design And Results: Eighty five AML patient samples were analyzed in this study.
Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Clin Cancer Res
December 2004
Département d'Hématologie Clinique, Laboratoire INSERM, Universitaire Paris 6, Hôpital Hôtel-Dieu, Paris, France.
Purpose: Recently, a new ABC protein, breast cancer resistance protein (BCRP), was described. But its prognosis is not known in acute myeloid leukemia (AML). In addition, the prognosis of P-glycoprotein (Pgp) and BCRP in patients treated homogeneously by the same anthracycline (daunorubicin, idarubicin, or mitoxantrone) during all of the treatment with aracytine is not known.
View Article and Find Full Text PDF